Tags: enzalutamide
Hem/Onc News
Ivosidenib Approved for Relapsed or Refractory Acute Myeloid Leukemia On July 20, the US Food and Drug Administration (FDA) approved ivosidenib (Tibsovo, Agios) for adults with […]
First-Line Use of Novel Hormonal Agents in Prostate Cancer: A Critical Appraisal
Abstract: Castration has been the hallmark of the treatment of advanced prostate cancer for nearly a century. Conventional surgical or medical castration for the management […]
Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced Prostate Cancer
H&O How common is resistance to abiraterone and enzalutamide in castration-resistant prostate cancer (CRPC)? ESA Approximately 15% to 25% of patients with CRPC do not respond to […]